<table id="id_29417304-bcff-441c-9751-0ac37671a977" width="559" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_b2eaffeb-eccb-4d86-82ba-c9e8229bbaa8">Table 5: Results of Drug Interaction Studies with Buggered Formulations of Didanosine: Effects of Coadministered Drug on Didanosine plasma AUC and Cmax Values</caption>
<col width="22.5%"></col>
<col width="21.6%"></col>
<col width="10.7%"></col>
<col width="18.6%"></col>
<col width="26.5%"></col>
<tbody>
<tr id="id_f1bb5264-7a41-42c8-bdd7-3d327bf750c4">
<td align="left" colspan="5" stylecode="Lrule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="italics">Drugs With Clinical Recommendations Regarding Coadministration (see <linkhtml href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4" title="PRECAUTIONS">PRECAUTIONS</linkhtml>, <linkhtml href="#i4i_section_id_d91d9f86-90ea-4ab6-b400-745b349d7afa">Drug Interactions</linkhtml> )</content>
</content>
</td>
</tr>
<tr id="id_9c14383f-7438-4644-a389-ba388bb4d652">
<td align="left" stylecode="Botrule Rrule" valign="top">Drug</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Didanosine Dosage</td>
<td align="left" stylecode="Botrule Rrule" valign="top">n</td>
<td align="left" stylecode="Botrule Rrule" valign="top">AUC Didanosine (95% CI)</td>
<td align="left" stylecode="Lrule Botrule" valign="top">Cmax of Didanosine (95% CI)</td>
</tr>
<tr id="id_715b98be-3d58-407e-887f-60202dc0e286">
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">allopurinol</content>,</paragraph>
<paragraph>Renally impaired, 300 mg/day</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">2</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑312%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑232%</td>
</tr>
<tr id="id_4397afe1-9a23-4e23-b9e9-de96ab209638">
<td align="left" stylecode="Botrule Rrule" valign="top">healthy volunteer, 300 mg/day for 7 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">400 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">14</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑113%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑69%</td>
</tr>
<tr id="id_d53bebbe-1d5d-4639-9b30-d824c2dfb52d">
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">ganciclovir</content>, 1000 mg q8h, 2 h after didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg q12h</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑111%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">NA</td>
</tr>
<tr id="id_05dec5e3-69b6-45c8-bb16-e5748b8a9d08">
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">methadone</content>, chronic maintenance dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">16, 10<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓57%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓66%</td>
</tr>
<tr id="id_466c7578-8f67-403c-9336-a412e7125bdd">
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">tenofovir</content>,<sup>b</sup> 300 mg once daily 1 h after didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">250<sup>c</sup> or 400 mg once daily for 7 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">14</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑44% (31, 59%)<sup>d</sup>
</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↔28% (11, 48%)<sup>d</sup>
</td>
</tr>
<tr id="id_09a9e9c5-ec4b-40a7-9f24-0551e024a07e">
<td align="left" colspan="5" stylecode="Lrule Botrule" valign="top">
<content stylecode="bold">No Clinically Significant Interactions Observed</content>
</td>
</tr>
<tr id="id_9419f86a-2543-410e-8881-dfad8d1b23fb">
<td align="left" stylecode="Botrule Rrule" valign="top">ciprofloxacin, 750 mg q12h for 3 days, 2 h before didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg q12h for 3 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">8<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓16%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓28%</td>
</tr>
<tr id="id_715c98cc-da78-472d-93f2-d2f590c1d75e">
<td align="left" stylecode="Botrule Rrule" valign="top">ininavir, 800 mg single dose simultaneous</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">16</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↔</paragraph>
</td>
<td align="left" stylecode="Lrule Botrule" valign="top">
<paragraph>↔</paragraph>
</td>
</tr>
<tr id="id_3c4abf98-1fdb-4e7e-a7ca-907cb5029a23">
<td align="left" stylecode="Botrule Rrule" valign="top">1 h before didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">16</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓17% (-27, -7%)<sup>d</sup>
</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓13% (-28, 5%)<sup>d</sup>
</td>
</tr>
<tr id="id_bd587532-d877-489b-99b5-02a45230db54">
<td align="left" stylecode="Botrule Rrule" valign="top">ketoconazole, 200 mg/day for 4 days, 2 h before didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">375 mg q12h for 4 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓12%</td>
</tr>
<tr id="id_8aaa22d8-9878-4f60-804e-2e65974e7304">
<td align="left" stylecode="Botrule Rrule" valign="top">loperamide, 4 mg q6h for 1 day</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓23%</td>
</tr>
<tr id="id_860b6212-ebf8-4f1c-ba93-65c0600a939b">
<td align="left" stylecode="Botrule Rrule" valign="top">metoclopramide, 10 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑13%</td>
</tr>
<tr id="id_1d63e51e-0c34-4f8e-be9b-c5f8f7c2a50f">
<td align="left" stylecode="Botrule Rrule" valign="top">ranitidine, 150 mg 2 h before didansine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">375 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑14%</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑13%</td>
</tr>
<tr id="id_fcacab0a-155f-4b3c-80ac-ea287aca5d20">
<td align="left" stylecode="Botrule Rrule" valign="top">rifabutin, 300 or 600 mg/day for 12 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">167 or 250 mg q12h for 12 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">11</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑13% (-1, 27%)</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑17% (-4, 38%)</td>
</tr>
<tr id="id_d9bc3e74-93c0-4ee5-8ede-1a2dcfaaf8b9">
<td align="left" stylecode="Botrule Rrule" valign="top">ritonavir, 600 mg q12h for 4 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg q12h for 4 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓13% (0, 23%)</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↓16% (5, 26%)</td>
</tr>
<tr id="id_578756cc-004c-4cc2-aad2-5f62cb59811c">
<td align="left" stylecode="Botrule Rrule" valign="top">stavudine, 40 mg q12h for 4 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">100 mg q12h for 4 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">10</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↔</td>
</tr>
<tr id="id_0b3129ab-eb44-4704-a28b-b7f58cbb7bc1">
<td align="left" stylecode="Botrule Rrule" valign="top">sulfamethoxazole, 1000 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">8<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↔</td>
</tr>
<tr id="id_396a1d33-fe35-4f1e-8b52-443e31c76e55">
<td align="left" stylecode="Botrule Rrule" valign="top">trimethoprim, 200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg single dose</td>
<td align="left" stylecode="Botrule Rrule" valign="top">8<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↑17% (-23, 77%)</td>
</tr>
<tr id="id_9bb96cc7-b202-4d1d-948c-bcfa14bc044c">
<td align="left" stylecode="Botrule Rrule" valign="top">zidovudine, 200 mg q7h for 3 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top"> 200 mg q12h for 3 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">8<sup>e</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="left" stylecode="Lrule Botrule" valign="top">↔</td>
</tr>
<tr id="id_073b7b91-137c-4a6d-b849-67e6234b943f">
<td align="left" colspan="5" stylecode="Botrule" valign="top">
<paragraph>↑ indicates increase<br/>↓ indicates decrease<br/>↔ indicates no change, or mean increase or decrease of &lt;10%.<br/>
<sup>a</sup> Parellel-group design; entries are subjects receiving combination and control regimens, respectively.<br/>
<sup>b</sup> tenogovir disoproxil fumarate<br/>
<sup>c</sup> patients &lt;60 kg with creatinine clearance &gt;60 mL/min.</paragraph>
<paragraph>
<sup>d</sup> 90% CI<br/>
<sup>e</sup> HIV-infected patients<br/>N/A Not available</paragraph>
</td>
</tr>
</tbody>
</table>